Fulvestrant: pharmacokinetics and pharmacology

Fulvestrant is a new type of oestrogen receptor (ER) antagonist with no agonist activity and a novel pharmacological profile. Fulvestrant has been shown to significantly reduce cellular levels of the ER and progesterone receptor in both preclinical studies and in clinical trials of postmenopausal wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, J F R, Harrison, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/
https://www.ncbi.nlm.nih.gov/pubmed/15094758
http://dx.doi.org/10.1038/sj.bjc.6601630
_version_ 1782172240664592384
author Robertson, J F R
Harrison, M
author_facet Robertson, J F R
Harrison, M
author_sort Robertson, J F R
collection PubMed
description Fulvestrant is a new type of oestrogen receptor (ER) antagonist with no agonist activity and a novel pharmacological profile. Fulvestrant has been shown to significantly reduce cellular levels of the ER and progesterone receptor in both preclinical studies and in clinical trials of postmenopausal women with primary breast cancer. This paper reviews the pharmacokinetics and metabolism of fulvestrant, which support the rationale for drug delivery as a single, once-monthly intramuscular injection, and show that this agent has minimal potential to be the subject, or cause, of significant cytochrome p450-mediated drug interactions.
format Text
id pubmed-2750771
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27507712009-09-24 Fulvestrant: pharmacokinetics and pharmacology Robertson, J F R Harrison, M Br J Cancer Original Article Fulvestrant is a new type of oestrogen receptor (ER) antagonist with no agonist activity and a novel pharmacological profile. Fulvestrant has been shown to significantly reduce cellular levels of the ER and progesterone receptor in both preclinical studies and in clinical trials of postmenopausal women with primary breast cancer. This paper reviews the pharmacokinetics and metabolism of fulvestrant, which support the rationale for drug delivery as a single, once-monthly intramuscular injection, and show that this agent has minimal potential to be the subject, or cause, of significant cytochrome p450-mediated drug interactions. Nature Publishing Group 2004-03 2004-03-05 /pmc/articles/PMC2750771/ /pubmed/15094758 http://dx.doi.org/10.1038/sj.bjc.6601630 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Robertson, J F R
Harrison, M
Fulvestrant: pharmacokinetics and pharmacology
title Fulvestrant: pharmacokinetics and pharmacology
title_full Fulvestrant: pharmacokinetics and pharmacology
title_fullStr Fulvestrant: pharmacokinetics and pharmacology
title_full_unstemmed Fulvestrant: pharmacokinetics and pharmacology
title_short Fulvestrant: pharmacokinetics and pharmacology
title_sort fulvestrant: pharmacokinetics and pharmacology
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/
https://www.ncbi.nlm.nih.gov/pubmed/15094758
http://dx.doi.org/10.1038/sj.bjc.6601630
work_keys_str_mv AT robertsonjfr fulvestrantpharmacokineticsandpharmacology
AT harrisonm fulvestrantpharmacokineticsandpharmacology

Ejemplares similares